10-Jun-2025
A promising therapeutic agent for treating excessive inflammation due to COVID-19
Institute of Science TokyoPeer-Reviewed Publication
Using SARS-CoV-2-infected obese mice as model for cytokine storm seen in COVID-19, Institute of Science Tokyo researchers demonstrate efficacy of iguratimod in reducing excess inflammation without reducing antiviral immune response. Iguratimod significantly improved survival in these mouse models compared to when steroids like dexamethasone were administered. Conventional steroids reduce the inflammation while also suppressing immune responses against SARS-CoV-2, leading to reduced viral clearance from the lungs. Iguratimod presents a promising therapy for COVID-19-related inflammatory syndrome.
- Journal
- European Journal of Pharmacology
- Funder
- Japan Agency for Medical Research and Development, Kobayashi Foundation, Asahi Kasei Pharma Corporation, Ayumi Pharmaceutical Corporation, Chugai Pharmaceutical Co Ltd, Nippon Boehringer Ingelheim Co Ltd, Taisho Pharmaceutical Co Ltd, AbbVie Inc, Eisai Inc, Eli Lilly, GlaxoSmithKline, Mitsubishi Tanabe Pharma Corporation, Ono Pharmaceutical Co Ltd, ImmunoForge, Novartis, Otsuka Pharmaceutical Co Ltd, Sony Corporation, Terumo Foundation for Life Sciences and Arts